190 related articles for article (PubMed ID: 10535397)
1. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Park KS; Kim CH; Lee MK; Shin CS; Park DJ; Kim SY; Cho BY; Lee HK
Metabolism; 1999 Oct; 48(10):1318-21. PubMed ID: 10535397
[TBL] [Abstract][Full Text] [Related]
2. Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism.
Lee EJ; Kim KR; Lee HC; Cho JH; Nam MS; Nam SY; Song YD; Lim SK; Huh KB
Metabolism; 1995 Nov; 44(11):1509-12. PubMed ID: 7476342
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
[TBL] [Abstract][Full Text] [Related]
4. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
6. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
7. The reduction in postprandial lipemia after exercise is independent of the relative contributions of fat and carbohydrate to energy metabolism during exercise.
Malkova D; Hardman AE; Bowness RJ; Macdonald IA
Metabolism; 1999 Feb; 48(2):245-51. PubMed ID: 10024090
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
[TBL] [Abstract][Full Text] [Related]
9. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Ahrén B
Acta Physiol Scand; 2001 Feb; 171(2):161-7. PubMed ID: 11350276
[TBL] [Abstract][Full Text] [Related]
10. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
Piatti PM; Monti LD; Davis SN; Conti M; Brown MD; Pozza G; Alberti KG
Diabetologia; 1996 Jan; 39(1):103-12. PubMed ID: 8720610
[TBL] [Abstract][Full Text] [Related]
11. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
[TBL] [Abstract][Full Text] [Related]
12. Effect of acute inhibition of lipolysis on operation of the glucose-fatty acid cycle in hepatic cirrhosis.
Farrer M; Fulcher GR; Johnson AJ; Record CO; Alberti KG
Metabolism; 1992 May; 41(5):465-70. PubMed ID: 1588824
[TBL] [Abstract][Full Text] [Related]
13. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Fulcher GR; Walker M; Farrer M; Johnson AS; Alberti KG
Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
[TBL] [Abstract][Full Text] [Related]
14. The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
Akanji AO; Osifo E; Kirk M; Hockaday TD
Metabolism; 1993 Apr; 42(4):426-34. PubMed ID: 8487664
[TBL] [Abstract][Full Text] [Related]
15. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
[TBL] [Abstract][Full Text] [Related]
16. The impact of forearm immobilization and acipimox administration on muscle amino acid metabolism and insulin sensitivity in healthy, young volunteers.
Dirks ML; Jameson TSO; Andrews RC; Dunlop MV; Abdelrahman DR; Murton AJ; Wall BT; Stephens FB
Am J Physiol Endocrinol Metab; 2024 Mar; 326(3):E277-E289. PubMed ID: 38231001
[TBL] [Abstract][Full Text] [Related]
17. The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
Berrish TS; Elliott C; Cooper BG; Reed JW; Orskov H; Alberti KG; Walker M
Diabet Med; 1993 Mar; 10(2):152-8. PubMed ID: 8458192
[TBL] [Abstract][Full Text] [Related]
18. Effects of Acipimox on the metabolism of free fatty acids and very low lipoprotein triglyceride.
Hannah JS; Bodkin NL; Paidi MS; Anh-Le N; Howard BV; Hansen BC
Acta Diabetol; 1995 Dec; 32(4):279-83. PubMed ID: 8750769
[TBL] [Abstract][Full Text] [Related]
19. Cyclic AMP infusion and blood sugar, serum insulin and serum nonesterified fatty acid responses to glucose in recent experimental hyperthyroid dogs.
Renauld A; Garrido D
Acta Physiol Pharmacol Ther Latinoam; 1992; 42(4):255-76. PubMed ID: 1343982
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lipolysis reduces beta1-adrenoceptor-mediated thermogenesis in man.
Schiffelers SL; Brouwer EM; Saris WH; van Baak MA
Metabolism; 1998 Dec; 47(12):1462-7. PubMed ID: 9867074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
